Semaglutide vs Tirzepatide

Semaglutide and tirzepatide are the two most prescribed GLP-1-based medications for weight loss in the United States, and both have transformed the landscape of medical weight management. While they share a common mechanism -- activating GLP-1 receptors to suppress appetite and slow digestion -- tirzepatide adds a second target by also activating GIP receptors, which may explain its higher average weight loss results. Choosing between them depends on your health profile, weight loss goals, budget, and how your body responds to treatment. Weight Method providers help you evaluate both options and select the best fit for your situation.

FDA-approved GLP-1 medications prescribed by licensed providers. Delivered to your door.

Take the Free Quiz

Free consultation · No commitment · Results in weeks

Patient
Patient
Patient
Patient
Patient
4.9/5

From 2,000+ patients · Semaglutide vs Tirzepatide is already seeing results

Licensed Providers
FDA-Approved Medications
Free Shipping
HIPAA Compliant
Updated March 2026Medically reviewed by licensed providers

Semaglutide and tirzepatide are FDA-approved GLP-1 medications for weight loss. Semaglutide achieved 14.9% body weight loss in the STEP 1 trial, while tirzepatide achieved 22.5% in SURMOUNT-1. Weight Method offers both medications starting at $297/month.

Semaglutide and tirzepatide are the two most prescribed GLP-1-based medications for weight loss in the United States, and both have transformed the landscape of medical weight management. While they share a common mechanism -- activating GLP-1 receptors to suppress appetite and slow digestion -- tirzepatide adds a second target by also activating GIP receptors, which may explain its higher average weight loss results. Choosing between them depends on your health profile, weight loss goals, budget, and how your body responds to treatment. Weight Method providers help you evaluate both options and select the best fit for your situation.

The most significant difference is the mechanism of action: semaglutide is a single-receptor GLP-1 agonist, while tirzepatide is a dual GIP/GLP-1 agonist. In head-to-head clinical data, tirzepatide produced approximately 5-7% greater average body weight loss than semaglutide at maximum doses. Semaglutide has a longer track record with more published long-term safety data, while tirzepatide is newer but has shown a similar side effect profile. At Weight Method, semaglutide starts at $297/month and tirzepatide at $349/month. Both are once-weekly injections, both require dose escalation, and both are FDA-approved for chronic weight management.

Semaglutide

MechanismGLP-1 receptor agonist that reduces appetite and slows gastric emptying
Avg. Weight Loss15-20% of body weight
FrequencyOnce weekly
Our Price$297/mo
Available Doses0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg
Side Effects
NauseaDiarrheaVomiting

Tirzepatide

MechanismDual GIP/GLP-1 receptor agonist that targets two incretin hormones
Avg. Weight Loss20-25% of body weight
FrequencyOnce weekly
Our Price$349/mo
Available Doses2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg
Side Effects
NauseaDiarrheaDecreased appetite

Ready to Get Started?

Answer a few quick questions to see if you qualify.

Check Eligibility

Your Treatment Options

Clinically proven GLP-1 medications at transparent prices

Starting at$297/mo
Semaglutide
Most PopularIn Stock

Semaglutide

Same active ingredient as Ozempic® & Wegovy®. Proven to reduce body weight by up to 15%.

  • Weekly injection
  • Gradual dose increase
  • Provider monitoring
  • Free shipping
Check Eligibility
Tirzepatide
In Stock

Tirzepatide

Same active ingredient as Mounjaro® & Zepbound®. Dual-action GLP-1/GIP for enhanced results.

  • Weekly injection
  • Dual hormone action
  • Provider monitoring
  • Free shipping
Check Eligibility

Frequently Asked Questions

Based on clinical trial data, tirzepatide produces higher average weight loss -- approximately 20-25% of body weight versus 15-20% with semaglutide. However, individual results vary significantly. Some patients respond exceptionally well to semaglutide, while others achieve better outcomes with tirzepatide. Your Weight Method provider can help determine which is most likely to work best for your specific health profile.

Both medications have similar safety profiles with comparable gastrointestinal side effects. Semaglutide has been on the market longer and has more long-term published data. Tirzepatide's clinical trial data shows a similar incidence of adverse events. Neither medication has shown significant safety concerns beyond those common to the GLP-1 class. Your provider will review your medical history to recommend the safest option for you.

Yes, this is a common approach. Some patients start with semaglutide due to its lower cost and longer track record, then switch to tirzepatide if they hit a weight loss plateau or want to accelerate results. Your Weight Method provider will manage the transition, adjusting doses appropriately to ensure a smooth and safe switch.

Tirzepatide is a newer medication with a more complex dual-receptor mechanism. It is also manufactured by Eli Lilly, whereas semaglutide is made by Novo Nordisk -- pricing reflects each manufacturer's strategy and patent status. At Weight Method, the price difference is $52/month ($297 vs $349), which many patients find worthwhile given tirzepatide's higher average weight loss.

The side effect profiles are very similar. Both commonly cause nausea, diarrhea, vomiting, and constipation, especially during dose escalation. Tirzepatide may cause slightly more injection site reactions. Both follow gradual dose increases specifically to reduce GI side effects. Most patients find that side effects diminish significantly within the first few weeks at each dose level.

Consider your weight loss goals, budget, and health history. Tirzepatide may be better if you are looking for maximum weight loss, have a BMI over 35, or have not seen adequate results with GLP-1-only medications. Semaglutide may be preferred if cost is a priority, you have a strong track record with GLP-1 therapy, or your provider recommends starting with a single-mechanism approach. Take the Weight Method quiz to receive a personalized recommendation.

Yes. Both semaglutide (as Wegovy) and tirzepatide (as Zepbound) are FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition -- no diabetes diagnosis required. Weight Method providers prescribe these medications for weight loss based on BMI and health criteria, not diabetes status.

Both semaglutide and tirzepatide are intended for long-term use. Clinical research shows that weight regain commonly occurs after discontinuation. Most providers recommend ongoing treatment as long as the medication is effective and well-tolerated. Your Weight Method provider will work with you on a sustainable plan, which may include eventual dose reduction or maintenance protocols.

Both medications can interact with insulin and sulfonylureas, increasing the risk of low blood sugar. They also slow gastric emptying, which may affect absorption of oral medications. Your Weight Method provider will review your full medication list during the consultation and adjust timing or doses as needed to avoid interactions.

After completing the online quiz, a licensed provider reviews your health history, BMI, current medications, and weight loss goals. They recommend semaglutide or tirzepatide based on your profile, explain the dosing schedule and potential side effects, and answer any questions. The entire process is virtual -- no in-person visit required -- and most patients are reviewed within 24 hours.

Start Your Treatment

Speak with a licensed provider today and find out if GLP-1 medications are right for you.

Get Started Now

Free consultation. No commitment.

Tools

Semaglutide vs Tirzepatide Dosage Calculator

Other Medications

SemaglutideTirzepatide